Home › NDC Lookup › RxCUI directory › RxCUI 1999651

12 HR doxylamine succinate 20 MG / pyridoxine hydrochloride 20 MG Extended Release Oral Ta... — RxCUI 1999651

RxNorm drug concept · Semantic clinical drug
RxCUI 1999651 Semantic clinical drug · SCD ● Current RxNorm concept 1 FDA product 4 package NDCs Snapshot Jul 14, 2026

This page is curated, coded, and maintained by

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI1999651
Official name12 HR doxylamine succinate 20 MG / pyridoxine hydrochloride 20 MG Extended Release Oral Tablet
Concept typeSemantic clinical drug (SCD)
RxNorm statusCurrent RxNorm concept
Also known as12 HR doxylamine succinate 20 MG / vit-B6 Hydrochloride 20 MG Extended Release Oral Tablet; doxylamine succinate 20 MG / pyridoxine HCl 12HR 20 MG Extended Release Oral Tablet; 12 HR doxylamine succinate 20 MG / vitamin B6 Hydrochloride 20 MG Extended Release Oral Tablet
FDA products mapped1
Package NDCs mapped4
Reported Medicaid activity (SDUD)8,032 prescriptions · 18 state & territory Medicaid programs · latest period Q4 2025
RxNorm release07/06/2026
Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Doxylamine and Pyridoxine: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist
  • It treats nausea and vomiting of pregnancy in women who have not improved with conservative management. It has not been studied in hyperemesis gravidarum.
  • Take it daily on an empty stomach with a glass of water, and swallow it whole. Don't crush, chew or split it. Take it every day rather than only when you feel sick, and follow your...
  • Sleepiness is the most common side effect. Avoid driving or operating heavy machinery until your provider says it's safe.
  • No. Alcohol and other sedating medicines can cause severe drowsiness, leading to falls or accidents. Never combine it with an MAO inhibitor.
📖 Read our full Doxylamine and Pyridoxine guide →

🕸️ Concept Web — How 12 HR doxylamine succinate 20 MG / pyridoxine hy... Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept 12 HR doxylamine succinate 20 MG / pyridoxine hydrochloride 20 MG Extended Release Oral Tablet RxCUI 1999651

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

  1. Ingredients 5

    The active substance itself — no strength, form, or brand attached yet.

    • Doxylamine 3642
    • Pyridoxine 684879
    • Doxylamine / pyridoxine 1375947
    • Doxylamine succinate 23665
    • Pyridoxine hydrochloride 203164
  2. Brand names 1

    The same medicine's trade names. A brand name alone says nothing about strength or form.

    • Bonjesta 1999652
  3. Dose forms 13

    The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.

    • Doxylamine / pyridoxine Extended Release Oral Tablet 1861644
    • Doxylamine succinate / pyridoxine hydrochloride Extended Release Oral Tablet 2646880
    • Doxylamine / pyridoxine Oral Product 1375944
    • Doxylamine / pyridoxine Pill 1375945
    • Doxylamine succinate / pyridoxine hydrochloride Oral Product 2659428
    • Doxylamine succinate / pyridoxine hydrochloride Pill 2662894
    • Doxylamine / pyridoxine Extended Release Oral Tablet [Bonjesta] 1999654
    • Doxylamine succinate / pyridoxine hydrochloride Extended Release Oral Tablet [Bonjesta] 2654225
    • +5 more in this family
  4. Clinical & branded drugs 4

    Ingredient + strength + dose form. These are the concepts real FDA products actually carry.

Showing up to 8 concepts per family — 18 of 23 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

  • Doxylamine succinate 20 MG SCDC · 1861643
  • Pyridoxine hydrochloride 20 MG SCDC · 350282
  • Doxylamine / pyridoxine Extended Release Oral Tablet SCDF · 1861644
  • Doxylamine succinate / pyridoxine hydrochloride Extended Release Oral Tablet SCDFP · 2646880
  • Doxylamine / pyridoxine Oral Product SCDG · 1375944
  • Doxylamine / pyridoxine Pill SCDG · 1375945
  • Doxylamine succinate / pyridoxine hydrochloride Oral Product SCDGP · 2659428
  • Doxylamine succinate / pyridoxine hydrochloride Pill SCDGP · 2662894

Brand-Name Concepts

📦 FDA Products & Package NDCs

1 product · 4 package NDCs
4 package NDCs map to RxCUI 1999651 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
Package NDC Package Brand / generic name Labeler Marketing start
55494-0120-10 100 TABLET, EXTENDED RELEASE in 1 BOTTLE (55494-120-10) BONJESTA Duchesnay USA, Inc. 2018-02-19
55494-0120-60 60 TABLET, EXTENDED RELEASE in 1 BOTTLE (55494-120-60) BONJESTA Duchesnay USA, Inc. 2018-02-19
55494-0120-94 1 BLISTER PACK in 1 CARTON (55494-120-94) / 4 TABLET, EXTEN... BONJESTA Duchesnay USA, Inc. 2025-02-26
55494-0120-99 6 TABLET, EXTENDED RELEASE in 1 BOTTLE (55494-120-99) BONJESTA Duchesnay USA, Inc. 2018-02-19
Observed labelers: Duchesnay USA, Inc. (4) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

💲 Pricing (NADAC)

NADAC is CMS's National Average Drug Acquisition Cost — roughly what pharmacies pay to buy the drug. It is an acquisition benchmark, not your copay.
Per ea · median
$11.1152
Range $11.1152–$11.1152 · middle 50% $11.1152–$11.1152 · 1 NDCs
Latest compatible distributions from the CMS NADAC file · dataset watermark 2026-07-10. Prices vary by package and pharmacy; a distribution is shown instead of one misleading number. Rows the dataset is silent on carry no price. No zero-cost conclusion should be drawn.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
  • A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
  • Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
  • Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
  • Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.